Can any game in December be a must-win? For Arizona Wildcats, facing UCLA might beWest Virginia knocks off No. 3 Gonzaga in overtimeJimmy Spithill introduces his new Red Bull Italy SailGP Team

People with ADHD are being warned not to share medication, as the country is affected by a worldwide shortage. ADHD New Zealand spokesman Darrin Bull said some people have had to pick which days they take their medicine, to try to make their prescription last longer. While some had been asking others to lend them some of their medicine, which needs to stop, he said. A worldwide shortage of methylphenidate, prescribed under the brand names Ritalin, Concerta or Teva, has lasted more than a year. And Bull said some New Zealanders who could not get their medication had expressed panic. "The ADHD medication is there for a purpose, and without it people can struggle - and really struggle," Bull said. "Some of the issues has been if they might try alternatives. We certainly on our social media site have got some of our community asking: 'can someone please lend me some medication?'." ADHD is estimated to affect more than 250,000 New Zealanders, and while a recent study found the amount of ADHD medication dispensed between 2006 and 2022 had increased tenfold, only about 20 percent of those with ADHD are thought to be receiving treatment. Medsafe warns that supplying prescription medicine over the internet and via social media - for sale or for free - is illegal, and so is purchasing or possessing it. Bull recommended that people affected by attention deficit hyperactivity disorder talk to a GP and a pharmacist, or find a non-medical alternative such as an ADHD coach, instead. ADHD New Zealand said alternatives to medication include support group discussions and advice, acupuncture, brain gym, counselling, diet, therapy and occupational therapy. The shortage is expected to last until mid-2025. Read more: New medication now funded Funding has been extended to now include an additional ADHD medication. Lisdexamfetamine (known by the brand name Vyvanse) has been available in New Zealand as a private non-funded alternative option to methylphenidate since 2023 , and the country's drug-buying agency Pharmac began subsidising it on 1 December. It has hopes the alternative drug will ease the pressure on the supply of other ADHD medicines. Pharmac noted that some lisdexamfetamine users who had already been buying it privately had previously reported supply problems, but said now that it is publicly funded, suppliers are required "to hold set amounts of stock in New Zealand to minimise risk of a supply issue". However Bull said ADHD New Zealand did not believe funding lisdexamfetamine would immediately help with the current medication shortage. Lisdexamfetamine needs to be prescribed by a psychiatrist, and: "The waiting lists to see a psychiatrist if you're an adult are quite long, and you might also find [there's] a substantial fee if you go private," he said. Pharmac said it expects the new medication will benefit more than 6000 people with ADHD in its first year of being funded, and about 13,000 people after five years. Sign up for Ngā Pitopito Kōrero, a daily newsletter curated by our editors and delivered straight to your inbox every weekday.

S&P/TSX composite down more than 100 points Tuesday, U.S. stock markets also lower

WASHINGTON (AP) — Senate Republican leader Mitch McConnell fell and sprained his wrist while walking out of a GOP luncheon on Tuesday, the latest in a series of medical incidents for him in recent years. McConnell, who is stepping down from his leadership post at the end of the year, was walking out of his weekly party lunch with Wyoming Sen. John Barrasso when he tripped and fell, Barrasso said, before walking back to his office on his own. Medical personnel were seen heading into his office minutes later. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.NFL Fans Worried About Justin Tucker After Concerning AppearanceThere’s no place like home for the holidays. And that may not necessarily be a good thing. In the wake of the very contentious and divisive 2024 presidential election, the winter holiday season could be a boon for some — a respite from the events of the larger world in the gathering of family and loved ones. Hours and even days spent with people who have played the largest roles in our lives. Another chapter in a lifetime of memories. That’s one scenario. For others, it’s something to dread. There is the likelihood of disagreements, harsh words, hurt feelings and raised voices looming large. Those who make a study of people and their relationships to each other in an increasingly complex 21st-century say there are choices that those with potentially fraught personal situations can make — things to do and things to avoid — that could help them and their families get through this time with a minimum of open conflict and a chance at getting to the point of the holidays in the first place. For those who feel strongly about the election’s outcome, and know that the people they would be spending the holiday with feel just as strongly in the other direction, take the time to honestly assess if you’re ready to spend time together in this moment. The answer might be that you’re not, and it might be better to take a temporary break, says Justin Jones-Fosu, author of “I Respectfully Disagree: How to Have Difficult Conversations in a Divided World.” “You have to assess your own readiness,” he says, “Each person is going be very different in this.” Keep focused on why you decided to go in the first place, Jones-Fosu says. Maybe it’s because there’s a relative there you don’t get to see often, or a loved one is getting up in age, or your kids want to see their cousins. Keeping that reason in mind could help you get through the time. If you decide getting together is the way to go, but you know politics is still a dicey subject, set a goal of making the holidays a politics-free zone and stick with it, says Karl Pillemer, a professor at Cornell University whose work includes research on family estrangement. Let’s be honest. Sometimes, despite best efforts and intentions to keep the holiday gathering politics- and drama-free, there’s someone who’s got something to say and is going to say it. In that case, avoid getting drawn into it, says Tracy Hutchinson, a professor in the graduate clinical mental health counseling program at the College of William & Mary in Virginia. “Not to take the hook is one of the most important things, and it is challenging,” she says. After all, you don’t have to go to every argument you’re invited to. If you risk getting caught up in the moment, consider engaging in what Pillemer calls “forward mapping,” involving strategy rather than tactics. Maybe imagine yourself six months from now looking back on the dinner. “Think about how you would like to remember this holiday,” he says. “Do you want to remember it with your brother and sister-in-law storming out and going home because you’ve had a two-hour argument?” Things getting intense? Defuse the situation. Walk away. And it doesn’t have to be in a huff. Sometimes a calm and collected time out is just what you — and the family — might need. Says Hutchinson: “If they do start to do something like that, you could say, ‘I’ve got to make this phone call. I’ve got to go to the bathroom. I’m going to take a walk around the block.’”

United by Water. Flowing as One.Kawhi Leonard return for LA Clippers presents new problem even if he gets healthy, ex-NBA star says

Scoreboard: Class AA boys wrestling rankingsWhoopi Goldberg was excited to show off her brand "new body" on The View this week, cheekily showing off guest Christian Siriano's work on her slimmed down figure on Thursday, Nov. 21. The fashion designer was welcomed by the whole panel of hosts decked out in clothing designed by him, surrounded by manikins showing off even more of his creations. 🤩🤩 SIGN UP for Parade's Trending News newsletter & we'll keep you in the know on the viral pop culture moments & celebrity news everyone is talking about 🗞️🗞️ "This is the most stunning set I've ever seen ever; that I've ever done," he told the women as he joined them during the episode. "Thank you so much, this is like incredible." "I didn't even know they look this good!" he added. "We did," Sara Haines assured him, "And that's why we're all wearing your stuff today as well." Goldberg then stood up to show off the flowing overcoat she wore, asking him, "You haven't seen me in my new body, have you?" The coat tied around the front, over a button-up shirt, and featured frilled, oversized cuffs. "And you look incredible," he replied, gushing, "This coat was made for you, it's yours, you get it!" The Sister Act alum opened up earlier this year about turning to medication to help her shed weight as the daytime talk show's cast discussed Oprah Winfrey’s An Oprah Special: Shame, Blame and the Weight Loss Revolution. Goldberg used Mounjaro after steroids helped her to hit 300 pounds while filming Till . Sunny Hostin also admitted to using the medication, originally developed for diabetics, to help her lose the 40 pounds she gained during the lockdown period of the pandemic. “I was horrified by the fact that I would have to come out on air. I was," she admitted at the time. But, in addition to her weight, her cholesterol had also increased—which Mounjaro also helped to lower. "I feel better, I think I look better, and that’s what this is about for people,” she admitted. Next: Whoopi Goldberg Makes a Bold Declaration About Elon Musk's 'Actual' Political Role

Stock market today: Wall Street’s rally stalls as Nasdaq pulls back from its record

SAN JOSE, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nutanix, Inc. (“Nutanix”) (Nasdaq: NTNX), a leader in hybrid multicloud computing, today announced its intention to offer, subject to market conditions and other factors, $750 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Nutanix also expects to grant the initial purchasers of the notes an option to purchase up to an additional $112.5 million aggregate principal amount of the notes within a 13-day period from, and including, the initial issuance date of the notes. The notes will be unsecured senior obligations of Nutanix. Interest will be payable semi-annually in arrears. The notes will mature on December 15, 2029, unless earlier converted, redeemed, or repurchased. The notes will be convertible at the option of holders, subject to certain conditions and during certain periods. Upon conversion, the notes may be settled in cash, shares of Nutanix’s Class A common stock or a combination of cash and shares of Nutanix’s Class A common stock, at Nutanix’s election. The interest rate, initial conversion rate and other terms of the notes are to be determined at the time of the pricing of the offering. Nutanix intends to use the net proceeds from the offering to (i) repurchase a portion of its outstanding 0.25% Convertible Senior Notes due 2027 (the “2027 notes”) concurrently with the pricing of the offering in separate and privately negotiated transactions with certain holders of its 2027 notes (the “concurrent note repurchases”) effected through one of the initial purchasers of the notes or its affiliate, acting as Nutanix’s agent, and (ii) repurchase up to $200.0 million of shares of Nutanix’s Class A common stock in privately negotiated transactions with institutional investors effected through one of the initial purchasers of the notes or its affiliate, acting as Nutanix’s agent, at a price per share equal to the last reported sale price of Nutanix’s Class A common stock on the Nasdaq Global Select Market on the date of the pricing of the notes (the “Share Repurchase”). Any such Share Repurchase would not reduce the amount available for future repurchases under Nutanix’s existing share repurchase program. Nutanix intends to use the remaining net proceeds from the offering for general corporate purposes, including working capital, capital expenditures and potential acquisitions. From time to time, Nutanix evaluates potential acquisitions of businesses, technologies or products. Currently, however, Nutanix does not have any understandings or agreements with respect to any acquisitions. The terms of the concurrent note repurchases are anticipated to be individually negotiated with each holder of the 2027 notes participating in the concurrent note repurchases, and will depend on several factors, including the market price of Nutanix’s Class A common stock and the trading price of the 2027 notes at the time of each such concurrent note repurchase. Certain holders of any 2027 notes that Nutanix agrees to repurchase may have hedged their equity price risk with respect to such 2027 notes and may, concurrently with the pricing of the notes, unwind all or part of their hedge positions by buying Nutanix’s Class A common stock and/or entering into or unwinding various derivative transactions with respect to Nutanix’s Class A common stock. Any repurchase of the 2027 notes, and the potential related market activities by holders of the 2027 notes participating in the concurrent note repurchases, together with the repurchase by Nutanix of any of its Class A common stock concurrently with the pricing of the notes, could increase (or reduce the size of any decrease in) the market price of Nutanix’s Class A common stock, which may affect the trading price of the notes at that time and the initial conversion price of the notes. Nutanix cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or its Class A common stock. No assurance can be given as to how much, if any, of the 2027 notes or the Class A common stock will be repurchased or the terms on which they will be repurchased. Neither the notes nor the shares of Nutanix’s Class A common stock potentially issuable upon conversion of the notes, if any, have been, or will be, registered under the Securities Act or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, such registration requirements. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful. About Nutanix Nutanix is a global leader in cloud software, offering organizations a single platform for running applications and managing data, anywhere. With Nutanix, companies can reduce complexity and simplify operations, freeing them to focus on their business outcomes. Building on its legacy as the pioneer of hyperconverged infrastructure, Nutanix is trusted by companies worldwide to power hybrid multicloud environments consistently, simply, and cost-effectively. Forward-Looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Nutanix’s financing plans, Nutanix’s ability to complete the offering, the timing and size of the offering, the concurrent note repurchases and the Share Repurchase, Nutanix’s intended use of the net proceeds of the offering. These statements involve risks and uncertainties that could cause actual results to differ materially, including, but not limited to, whether Nutanix will be able to consummate the offering, the final terms of the offering, the satisfaction of customary closing conditions with respect to the offering of the notes, prevailing market conditions, the anticipated use of the net proceeds of the offering of the notes, which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in the United States or internationally. Forward-looking statements may be identified by the use of the words “may,” “will,” “expect,” “intend,” and other similar expressions. These forward-looking statements are based on estimates and assumptions by Nutanix’s management that, although believed to be reasonable, are inherently uncertain and subject to a number of risks. Actual results may differ materially from those anticipated or predicted by Nutanix’s forward-looking statements. All forward-looking statements are subject to other risks detailed in Nutanix’s Annual Report on Form 10-K for the fiscal year ended July 31, 2024, and the risks discussed in Nutanix’s other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Nutanix undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof, except as required by applicable law. © 2024 Nutanix, Inc. All rights reserved. Nutanix, the Nutanix logo, and all Nutanix product and service names mentioned herein are registered trademarks or unregistered trademarks of Nutanix, Inc. (“Nutanix”) in the United States and other countries. Other brand names or marks mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s). This press release is for informational purposes only and nothing herein constitutes a warranty or other binding commitment by Nutanix. Investor Contact: Richard Valera ir@nutanix.com Media Contact: Lia Bigano pr@nutanix.comPRINCETON JUNCTION, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE: MG)—a leading "one source" multinational provider of integrated technology-enabled asset protection solutions, is pleased to announce the appointment of Hani Hammad as the Company’s Chief Operating Officer (COO), effective January 1, 2025. This appointment follows the recent hiring of Natalia Shuman as the Company’s President and Chief Executive Officer (CEO), to whom Mr. Hammad will report directly. In addition to his role as COO, Mr. Hammad will continue serving as MISTRAS Group Executive Vice President. Spearheading Operational Excellence In his role as COO, Mr. Hammad will continue to drive operational excellence, strategic growth, and a culture of innovation at MISTRAS Group. Working closely with both executive and operational management, Mr. Hammad will shape and implement strategies that expand market share by delivering exceptional customer value while overseeing the company’s services and data analytics solutions. MISTRAS Group Executive Chairman of the Board, Manuel (Manny) N. Stamatakis, commented, “With his value-creation approach to operational leadership, Mr. Hammad consistently uncovers growth opportunities and drives impactful changes that accelerate our organizational progress. The Board of Directors and I are confident in his ability to generate high-margin value for MISTRAS Group and our shareholders.” “MISTRAS Group leads the industry due to the strength and expertise of our operational teams,” Hani Hammad stated. “My role is to enhance our resources' position to succeed, emphasizing continuous improvement through innovation and delivering differentiated, high-value solutions that meet our customers' evolving needs.” An Architect of Efficiency and Effectiveness Mr. Hammad joined MISTRAS Group after a tenure with global consultancy firm AlixPartners and recently served as MISTRAS Group’s Chief Transformation Officer (CTO). He has been pivotal in identifying and executing transformational value-creation opportunities, leading various process efficiency and organizational optimization initiatives, and driving MISTRAS’ investments in high-margin growth areas. The goal now is to further engrain the transformational, continuous improvement culture initiated by Project Phoenix into the company’s day-to-day operations on a permanent basis. This will help create additional value creation opportunities while sustaining the progress already made. He was instrumental in designing and managing MISTRAS Group’s Project Phoenix EBITDA Improvement Program, which identified over $47M in annual run rate EBITDA improvement opportunities. His expertise in facilitating operational and financial transformations has made him a trusted advisor in the industry, adept at leading complex value creation programs through challenging landscapes, including mergers & acquisitions and strategic market repositioning. About MISTRAS Group, Inc. - One Source for Asset Protection Solutions® MISTRAS Group, Inc. (NYSE: MG) is a leading "one source" multinational provider of integrated technology-enabled asset protection solutions, helping to maximize the safety and operational uptime for civilization’s most critical industrial and civil assets. Backed by an innovative, data-driven asset protection portfolio, proprietary technologies, strong commitment to Environmental, Social, and Governance (ESG) initiatives, and a decades-long legacy of industry leadership, MISTRAS leads clients in the oil and gas, aerospace and defense, renewable and nonrenewable power, civil infrastructure, and manufacturing industries towards achieving operational and environmental excellence. By supporting these organizations that help fuel our vehicles and power our society; inspecting components that are trusted for commercial, defense, and space craft; building real-time monitoring equipment to enable safe travel across bridges; and helping to propel sustainability, MISTRAS helps the world at large. MISTRAS enhances value for its clients by integrating asset protection throughout supply chains and centralizing integrity data through a suite of Industrial IoT-connected digital software and monitoring solutions. The company’s core capabilities also include non-destructive testing field and in-line inspections enhanced by advanced robotics, laboratory quality control and assurance testing, sensing technologies and NDT equipment, asset and mechanical integrity engineering services, and light mechanical maintenance and access services. For more information about how MISTRAS helps protect civilization’s critical infrastructure and the environment, visit https://www.mistrasgroup.com/ . Contact: Nestor S. Makarigakis Group Vice President, Marketing and Communications MISTRAS Group, Inc. marcom@mistrasgroup.com +1 (609) 716-4000

Nutanix Announces Proposed $750 Million Convertible Senior Notes Offering

PDUFA goal date is July 27, 2025 COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) in adult growth hormone deficiency (GHD) for TransCon hGH (lonapegsomatropin-tcgd; marketed as SKYTROFA ® for pediatric GHD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025. "This marks another step towards achieving our objective to expand SKYTROFA's label beyond pediatric GHD and expand its reach to address new groups of patients,” said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. "Adult GHD is an undertreated condition associated with significant comorbidities and higher annual healthcare costs compared to the 5-10% of patients who receive treatment, indicative of the high unmet need.” The sBLA submission is based on results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial that compared the efficacy and safety of weekly TransCon hGH with weekly placebo and daily human growth hormone (hGH) in adults with GHD. The trial evaluated 259 adults with GHD aged 23 to 80 years old, randomized 1:1:1, titrated to receive a target fixed dose of TransCon hGH, placebo, or daily hGH based on age and oral estrogen intake with approximately equivalent hGH mg/week for TransCon hGH and daily hGH. TransCon hGH demonstrated superiority on its primary efficacy and key secondary efficacy endpoints at Week 38, with TransCon hGH-treated participants showing a statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared to placebo. In the trial, TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily hGH treatment. About Adult Growth Hormone Deficiency Growth hormone plays an essential role in the health of children and adults, promoting normal growth in children and maintenance of normal body composition and cardiometabolic health throughout adulthood. In adults, growth hormone boosts protein production, promotes fat utilization, enhances muscle mass, and helps regulate blood sugar levels. Adult GHD is a condition in which an individual's body does not produce enough growth hormone. Symptoms and morbidity can include central obesity, metabolic syndrome, decreased bone density, alterations in lipid profile and markers of cardiovascular risk, fatigue, general weakness, lack of muscle tone, and psychological symptoms such as cognitive impairment, social isolation, lack of motivation, and depression. 1 About Ascendis Pharma A/S Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the PDUFA goal date for SKYTROFA, (ii) Ascendis' objective to expand SKYTROFA's label and reach to address new groups of patients, (iii) Ascendis' ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company, and (iv) Ascendis' use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' prospectus supplement filed on September 20, 2024 and Ascendis' current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC on February 7, 2024. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and SKYTROFA ® , are trademarks owned by the Ascendis Pharma group. © December 2024 Ascendis Pharma A/S.